Routine immunization profile: Luxembourg

*Second dose +6M Routine immunization profile Luxembourg Progress towards achieving European Vaccine Action Plan goals, 2017 Goal Indicator Status Goal Indicator Status 1 Sustain polio-free status a (Current risk) Yes (Intermediate) 4 Meets vaccination coverage targets DTP3 national immunization coverage ≥95%d ≥90% DTP3 coverage achieved in ≥90% of districts*e Yes Yes ND 2 Measles elimination statusb Eliminated 5 Make evidence-based decisions about introduction of new vaccines**e NITAG made a recommendation about PCV NITAG made a recommendation about RV NITAG made a recommendation about HPV Yes Yes Yes YesRubella elimination status b Eliminated 3 Control hepatitis B infectionc Validation pending 6 Achieve financial sustainability of the national immunization programme***c Yes * Subnational coverage data are not collected; however, no major differences between national and subnational coverage were detected in a 2012 coverage surveyi **New vaccines introduced or not introduced based on NITAG evidence-based recommendations ***Country self-sufficient for procuring routine vaccines Demographic, income and health expenditure summary, 2017 Total Populationf 583 455 Live births 6618 Surviving infants 6598 <5 years 33 137 <15 years 95 938 Neonatal mortality rate (per 1000 live births)f 1.7 Infant mortality rate (per 1000 live births)f 2.1 Number of districtse 0 GNI (per capita, in USD)g 70 790 Health spending as % of total government expenditureg 12 Immunization schedule, 2017e,i 2M DTaPHibHepBIPV, PCV, Rotavirus 3M DTaPHibHepBIPV, Rotavirus 4M DTaPHibIPV, PCV 12M MMRV, PCV 13M DTaPHibHepBIPV, MenC_conj 15-23M MMRV 5-6Y DTaPIPV 11-13Y HPV* 15-16Y DTaPIPV, MenC_conj Routine immunization profile Luxembourg Vaccine coverage estimates, 2013-2017d Number of reported cases of vaccine- preventable diseases, 2013-2017e,i 2013 2014* 2015 2016 2017 Measles 0 2 0 0 4 Mumps 5 0 0 1 Rubella 0 0 0 0 0 Congenital rubella syndrome 0 0 0 0 Diphtheria 0 0 0 0 Tetanus 0 0 0 0 Pertussis 29 6 0 7 18 Hepatitis A 3 5 6 7 Varicella 0 0 ND 0 *No JRF submittedND NR50 0100 2013 2014 2015 2016 2017 BCG NR NR NR NR NR HepB-BD NR NR NR NR NR DTP1 99 99 99 99 99 DTP3 99 99 99 99 99 HepB3 94 94 94 94 94 Hib3 99 99 99 99 99 Pol3 99 99 99 99 99 PCV3 95 95 95 95 95 Rotac 89 89 89 89 89 RCV1 99 99 99 99 99 MCV1 99 99 99 99 99 MCV2 86 86 86 86 86 Number of reported measles, mumps and rubella casese and MCV coverage estimatesd, 2013-2017 *No JRF submitted Number of reported diphtheria, tetanus and pertussis casese and DTP3 coverage estimatesd, 2013-2017 *No JRF submitted 0 20 40 60 80 100 0 1 2 3 4 5 6 2013 2014* 2015 2016 2017 % c ov er ag e N um be r o f c as es Year Measles Mumps Rubella MCV1 coverage MCV2 coverage 0 20 40 60 80 100 0 5 10 15 20 25 30 35 2013 2014* 2015 2016 2017 % c ov er ag e N um be r o f c as es Year Diptheria Tetanus Pertussis DTP3 coverage DTP1-DTP3 dropout rate, 2013-2017d Note: Dropout rate is calculated using WUENIC 0 0 0 0 0 0 1 2 3 4 5 2013 2014 2015 2016 2017 DTP1-DTP3 dropout rate (%) Ye ar Surveillance with laboratory confirmation of cases, 2017e Measles Yes Rubella Yes Congenital rubella syndrome Yes Rotavirus Yes Invasive meningococcal disease Yes Invasive pneumococcal disease Yes Invasive Haemophilus influenzae disease Yes Note: Case-based surveillance (with laboratory confirmation of cases) assessed for measles, rubella, and congenital rubella syndrome. Hospital-based sentinel surveillance and/or population-based surveillance (both with laboratory confirmation of cases) assessed for rotavirus, invasive meningococcal disease, invasive pneumococcal disease, and invasive Haemophilus influenzae disease. Routine immunization profile Luxembourg Vaccine stockouts by administrative levele, 2013-2017 *Data on HPV stockouts have only been collected in JRF since 2016 **No JRF submitted No stockout Subnational level stockout only National level stockout only Stockout at both levels NR ND 2013 2014** 2015 2016 2017 BCG No ND ND ND DTP No ND ND ND HepB No ND ND ND Hib No ND ND ND Pneumo No ND ND ND Rota No ND ND ND OPV NR NR NR NR IPV No ND ND ND Measles No ND ND ND HPV * * * ND ND TT No ND ND ND Immunization system characteristics, 2017 Sustained access to WHO accredited polio, measles, and rubella laboratoriesh Yes NITAG in place that meets six WHO criteriae No National system in place to monitor AEFIse ND Communication plan in place to respond to vaccine safety-related eventse ND Vaccine hesitancy assessment performed within last 5 years e ND Mandatory proof of immunization at school entrye No Note: The six WHO NITAG criteria are 1. legislative or administrative basis for the advisory group; 2. formal written terms of reference; 3. at least five different areas of expertise represented among core members; 4. at least one meeting per year; 5. circulation of the agenda and background documents at least one week prior to meetings; 6. mandatory disclosure of any conflict of interest Abbreviations AEFI Adverse event following immunization MCV2 measles-mumps-rubella vaccine, second dose BCG Bacille Calmette-Guerin vaccine for tuberculosis MenC_conj Meningococcal C conjugate vaccine CRS congenital Rubella Syndrome MMR measles-mumps-rubella vaccine DT diptheria-tetanus-containing vaccine MMRV measles-mumps-rubella-varicella vaccine DTP diptheria-tetanus-pertussis-containing vaccine ND Data not available DTP1 diphtheria-tetanus-pertussis-containing vaccine, first dose NITAG National Immunization Technical Advisory Group DTP3 diphtheria-tetanus-pertussis-containing vaccine, third dose NR Not relevant as vaccine not included in immunization schedule GNI Gross national income OPV oral polio vaccine HepB hepatitis B PCV pneumococcal conjugate vaccine HepB3 hepatitis B vaccine, third dose PCV3 pneumococcal conjugate vaccine , third dose HepB-BD hepatitis B vaccine, birth dose Pol3 polio-containing vaccine, third dose Hib Haemophilus influenzae type b RCV1 rubella-containing vaccine, first dose Hib3 Haemophilus influenzae type b vaccine, third dose Rotac rotavirus vaccine-complete series HPV human papillomavirus Td tetanus-diphtheria-containing vaccine IPV inactivated polio vaccine TT tetanus toxoid vaccine MCV measles-containing vaccine W,M,Y Weeks, Months, Years MCV1 measles-mumps-rubella vaccine, first dose Routine immunization profile Luxembourg Data sources a European Regional Commission for Certification of Poliomyelitis eradication (RCC) meeting report: www.euro.who.int/32ndRCC b European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thRVC c European Vaccine Action Plan 2015-2020 Midterm report d WHO/UNICEF Estimates of National Immunization Coverage (WUENIC): (http://www.who.int/immunization/monitoring_surveillance/data/en/) e WHO/UNICEF Joint Reporting Form on immunization (JRF) f World Population Prospects: The 2017 Revision, New York, United Nations g World Bank, World Development Indicators h Polio Laboratory Network: www.euro.who.int/poliolabnetwork & Personal communication based on annual accreditation process of the European Measles and Rubella Laboratory Network i Communication with the country † The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Map disclaimer ©World Health Organization 2019